Miltefosine: A novel treatment option for mast cell-mediated diseases

Journal of Dermatological Treatment

Volumn 24, Issue 4, 2013, Pages 244-249

  Maurer, Marcus ^a   Magerl, Markus ^a   Metz, Martin ^a   Weller, Karsten ^a   Siebenhaar, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allergic diseases; Mast cells; Miltefosine; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; CLOBETASOL; CORTICOSTEROID; MILTEFOSINE; PLACEBO;

ADULT; ATOPIC DERMATITIS; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; HUMAN; IN VITRO STUDY; LIPID RAFT; MAST CELL; MAST CELL DEGRANULATION; MASTOCYTOSIS; MORPHOMETRICS; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; URTICARIA;

ANTINEOPLASTIC AGENTS; DERMATITIS, ATOPIC; HUMANS; MAST CELLS; MASTOCYTOSIS; PHOSPHORYLCHOLINE; URTICARIA PIGMENTOSA;

EID: 84880221843     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.671909     Document Type: Review

References (8)

1. Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, dos Santos RV, et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol. 2009;129:496-498.
2. Hartmann K, Siebenhaar F, Belloni B, Brockow K, Eben R, Hartmann B, et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: A randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2010;162:185-190.
3. Dolle S, Hoser D, Rasche C, Loddenkemper C, Maurer M, Zuberbier T, et al. Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy. 2010;65: 1158-1165.
4. Magest M, Maurer M, Randomized double-blind, placebocontrolled study of safety and efficacy of miltefosine in antihistamine-resistant chronic. Journal of European Academy of Dermatology and Venerology; in press.
5. Harvima IT, Nilsson G, Naukkarinen A. Role of mast cells and sensory nerves in skin inflammation. G Ital Dermatol Venereol. 2010;145:195-204.
6. Menez C, Buyse M, Farinotti R, Barratt G. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids. 2007;42:229-240.
7. Silveira ESAM, Mazucato VM, Jamur MC, Oliver C. Lipid rafts in mast cell biology. J Lipids. 2011;2011:752906.
8. Baumer W, Wlaz P, Jennings G, Rundfeldt C. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models. Eur J Pharmacol. 2010;628:226-232.